<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687035</url>
  </required_header>
  <id_info>
    <org_study_id>2010-12 S3iCAP</org_study_id>
    <nct_id>NCT02687035</nct_id>
  </id_info>
  <brief_title>PARTNER II Trial: S3iCAP</brief_title>
  <acronym>PII S3i CAP</acronym>
  <official_title>The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves: Continued Access Program for SAPIEN 3 Intermediate Risk (S3iCAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following completion of enrollment in the PARTNER II SAPIEN 3 intermediate risk trial, this&#xD;
      trial provided continued access to treatment for subjects with severe aortic stenosis who&#xD;
      were at intermediate surgical risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, single arm registry will provide continued access of the Edwards SAPIEN 3&#xD;
      Transcatheter Heart Valve and delivery systems to severe aortic stenosis patients at&#xD;
      intermediate risk for standard aortic valve replacement. Patient data will be entered into&#xD;
      the TVT Registry (TVTR) from screening through 1 year including the collection of 5 year&#xD;
      follow-up through CMS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
    <description>Number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Valve Reintervention</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with aortic valve reintervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Valve Reintervention</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with aortic valve reintervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annular Dissection</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with annular dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Dissection</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with aortic dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Access Vascular Site Complication</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with major vascular complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Vascular Surgery or Intervention</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with unplanned vascular surgery or intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retroperitoneal Bleeds</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with retroperitoneal bleed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Bleed</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with gastrointestinal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genitourinary Bleed</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with genitourinary bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding at Access Site</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with bleeding at the access site</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1822</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN S3 valve</intervention_name>
    <description>Transcatheter aortic valve replacement</description>
    <arm_group_label>TAVR</arm_group_label>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
    <other_name>Transcatheter aortic valve replacement</other_name>
    <other_name>SAPIEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be covered by Medicare. This will enable Edwards to link to the CMS&#xD;
             database for long term follow-up through 5 years. No other insurance provider will be&#xD;
             accepted.&#xD;
&#xD;
          2. Assessment of intermediate surgical risk defined as STS 4-8% or heart team assessment&#xD;
             of intermediate risk factors.&#xD;
&#xD;
          3. Patient has senile degenerative aortic valve stenosis with echocardiographically&#xD;
             derived criteria: mean gradient &gt; 40 mmHg or jet velocity greater than 4.0 m/s and an&#xD;
             initial aortic valve area (AVA) of &lt; 0.8 cm2 or indexed EOA &lt; 0.5 cm2/m2. Qualifying&#xD;
             echo must be within 60 days of the date of the procedure.&#xD;
&#xD;
          4. Aortic valve annulus area range (273mm2-680 mm2) per 3D imaging (echo, CT, or MRI).&#xD;
&#xD;
          5. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA&#xD;
             Functional Class II or greater.&#xD;
&#xD;
          6. The heart team agrees (and verified in the case review process) that valve&#xD;
             implantation will likely benefit the patient.&#xD;
&#xD;
          7. Heart team agrees (a priori) on treatment strategy for concomitant coronary disease&#xD;
             (if present).&#xD;
&#xD;
          8. The study patient or the study patient's legal representative has been informed of the&#xD;
             nature of the study, agrees to its provisions and has provided written informed&#xD;
             consent as approved by the Institutional Review Board (IRB) of the respective clinical&#xD;
             site.&#xD;
&#xD;
          9. The study patient agrees to comply with all required post-procedure follow-up visits&#xD;
             including annual visits through 5 years and analysis close date visits, which will be&#xD;
             conducted as a phone follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Heart team assessment of inoperability (including examining cardiac surgeon).&#xD;
&#xD;
          2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended&#xD;
             treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥&#xD;
             twice normal in the presence of MB elevation and/or troponin level elevation (WHO&#xD;
             definition)].&#xD;
&#xD;
          3. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is&#xD;
             non-calcified.&#xD;
&#xD;
          4. Mixed aortic valve disease (aortic stenosis and aortic re-regurgitation with&#xD;
             predominant aortic regurgitation &gt;3+).&#xD;
&#xD;
          5. Pre-existing mechanical or bioprosthetic valve in any position.&#xD;
&#xD;
          6. Complex coronary artery disease:&#xD;
&#xD;
               1. Unprotected left main coronary artery&#xD;
&#xD;
               2. Syntax score &gt; 32 (in the absence of prior revascularization)&#xD;
&#xD;
          7. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is&#xD;
             performed within 30 days of the index procedure (unless part of planned strategy for&#xD;
             treatment of concomitant coronary artery disease). Implantation of a permanent&#xD;
             pacemaker or ICD is not considered exclusion criteria.&#xD;
&#xD;
          8. Any patient with a balloon valvuloplasty (BAV) &lt; 30 days of the procedure (unless BAV&#xD;
             is a bridge to procedure after a qualifying ECHO).&#xD;
&#xD;
          9. Patients with planned concomitant surgical or transcatheter ablation for atrial&#xD;
             fibrillation.&#xD;
&#xD;
         10. Leukopenia (WBC &lt; 3000 cell/mL), acute anemia (Hgb &lt; 9 g/dL), thrombocytopenia (Plt &lt;&#xD;
             50,000 cell/mL).&#xD;
&#xD;
         11. Hypertrophic cardiomyopathy with or without obstruction (HOCM).&#xD;
&#xD;
         12. Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
             ventilation or mechanical heart assistance within 30 days of screening evaluation.&#xD;
&#xD;
         13. Need for emergency surgery for any reason.&#xD;
&#xD;
         14. Severe ventricular dysfunction with LVEF &lt; 20%.&#xD;
&#xD;
         15. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.&#xD;
&#xD;
         16. Active upper GI bleeding within 3 months (90 days) prior to procedure.&#xD;
&#xD;
         17. A known contraindication or hypersensitivity to all anticoagulation regimens, or&#xD;
             inability to be anticoagulated for the study procedure.&#xD;
&#xD;
         18. Native aortic annulus size &lt; 16 mm or &gt; 28mm as measured by echocardiogram.&#xD;
&#xD;
         19. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic&#xD;
             attack (TIA) within 6 months (180 days) of the procedure.&#xD;
&#xD;
         20. Renal insufficiency (creatinine &gt; 3.0 mg/dL) and/or renal replacement therapy at the&#xD;
             time of screening.&#xD;
&#xD;
         21. Estimated life expectancy &lt; 24 months (730 days) due to carcinomas, chronic liver&#xD;
             disease, chronic renal dis-ease or chronic end stage pulmonary disease.&#xD;
&#xD;
         22. Expectation that patient will not improve despite treatment of aortic stenosis.&#xD;
&#xD;
         23. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch&#xD;
             atheroma [especially if thick (&gt; 5 mm), protruding or ulcerated] or narrowing&#xD;
             (especially with calcification and surface irregularities) of the abdominal or&#xD;
             thoracic aorta, severe &quot;unfolding&quot; and tortuosity of the thoracic aorta.&#xD;
             (Transfemoral)&#xD;
&#xD;
         24. Iliofemoral vessel characteristics that would preclude safe placement of 14F or 16F&#xD;
             introducer sheath such as severe obstructive calcification, severe tortuosity or&#xD;
             min-imum average vessel size less than 5.5 mm. (Transfem-oral).&#xD;
&#xD;
         25. Currently participating in an investigational drug or an-other device study. Note:&#xD;
             Trials requiring extended fol-low-up for products that were investigational, but have&#xD;
             since become commercially available, are not considered investigational trials.&#xD;
&#xD;
         26. Active bacterial endocarditis within 6 months (180 days) of procedure.&#xD;
&#xD;
         27. Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis.&#xD;
&#xD;
         28. Inability to tolerate anticoagulation/antiplatelet therapy.&#xD;
&#xD;
         29. For transfemoral approach only: Femoro-iliac vessels &lt; 5.5 mm for the 23 mm and the 26&#xD;
             mm system and &lt; 6.0 mm for the 29 mm system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susheel Kodali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem Research Institute</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health-Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group, Inc./ St. Vincent Heart Center of Indiana, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Saint Marys Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City Mid America</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/ Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop-University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Long Island Jewish Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Charleston</name>
      <address>
        <city>Charleston</city>
        <state>North Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular Research Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <results_first_submitted>December 22, 2020</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S3iCAP</keyword>
  <keyword>SAPIEN 3</keyword>
  <keyword>Transfemoral</keyword>
  <keyword>Commander</keyword>
  <keyword>Certitude</keyword>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>THV</keyword>
  <keyword>Transcatheter Heart Valve</keyword>
  <keyword>TVT</keyword>
  <keyword>TVTR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02687035/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from January 2015 to August 2016. Subjects in this trial were entered into the TVT Registry. Of the 1822 subjects enrolled in the trial, 1814 subjects received the study device.</recruitment_details>
      <pre_assignment_details>Participants that did not receive an Edwards device were not followed in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SAPIEN 3</title>
          <description>Patients at intermediate surgical risk receiving the SAPIEN S3 valve with Commander or Certitude delivery system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1822"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1638"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive Study Device</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1814 subjects received the SAPIEN 3 valve</population>
      <group_list>
        <group group_id="B1">
          <title>SAPIEN 3</title>
          <description>Intermediate risk patients receiving the SAPIEN S3 valve with Commander or Certitude delivery system.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1814"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="786"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1705"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Society of Thoracic Surgeons (STS) Score</title>
          <description>The Society of Thoracic Surgeons (STS) Score measures patient risk of mortality or morbidity at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk of operative mortality.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="682"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1041"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Assessed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death</title>
        <description>Number of deaths</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Number of deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death</title>
        <description>Number of deaths</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Number of deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroke</title>
        <description>Number of participants with stroke</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Number of participants with stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroke</title>
        <description>Number of participants with stroke</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Number of participants with stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Valve Reintervention</title>
        <description>Number of participants with aortic valve reintervention</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Valve Reintervention</title>
          <description>Number of participants with aortic valve reintervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Valve Reintervention</title>
        <description>Number of participants with aortic valve reintervention</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Valve Reintervention</title>
          <description>Number of participants with aortic valve reintervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annular Dissection</title>
        <description>Number of participants with annular dissection</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Annular Dissection</title>
          <description>Number of participants with annular dissection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Dissection</title>
        <description>Number of participants with aortic dissection</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Dissection</title>
          <description>Number of participants with aortic dissection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Access Vascular Site Complication</title>
        <description>Number of participants with major vascular complications</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Access Vascular Site Complication</title>
          <description>Number of participants with major vascular complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unplanned Vascular Surgery or Intervention</title>
        <description>Number of participants with unplanned vascular surgery or intervention</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Unplanned Vascular Surgery or Intervention</title>
          <description>Number of participants with unplanned vascular surgery or intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retroperitoneal Bleeds</title>
        <description>Number of participants with retroperitoneal bleed</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Retroperitoneal Bleeds</title>
          <description>Number of participants with retroperitoneal bleed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Bleed</title>
        <description>Number of participants with gastrointestinal bleeding</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Bleed</title>
          <description>Number of participants with gastrointestinal bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genitourinary Bleed</title>
        <description>Number of participants with genitourinary bleeding</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Genitourinary Bleed</title>
          <description>Number of participants with genitourinary bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding at Access Site</title>
        <description>Number of participants with bleeding at the access site</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAPIEN 3</title>
            <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding at Access Site</title>
          <description>Number of participants with bleeding at the access site</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All events are reported at 1 year.</time_frame>
      <desc>This trial used the TVT Registry Data Collection Form and database. On the TVT Registry Data Collection Form, clinical sites do not report the seriousness of adverse events, therefore seriousness was determined by the sponsor based on the standardized definition of a serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>SAPIEN 3</title>
          <description>Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="818" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Conduction/native pacer disturbance requiring pacemaker</sub_title>
                <counts group_id="E1" events="220" subjects_affected="219" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Conduction/native pacer disturbance requiring Implantable Cardioverter Defibrillator</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Coronary Compression or Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Major Vascular Complication</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="50" subjects_affected="49" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Undetermined Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Stroke</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Non-valve Related Readmission</sub_title>
                <counts group_id="E1" events="458" subjects_affected="354" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Unplanned Vascular Surgery or Intervention</sub_title>
                <counts group_id="E1" events="54" subjects_affected="53" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Unplanned Other Cardiac Surgery or Intervention</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Percutaneous Coronary Intervention</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Valve Related Readmission</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>New Requirement for Dialysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Aortic Valve Re-intervention</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation with or w/o Tamponade</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Major Bleeding Event</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Life Threatening Bleeding</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Annular Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1814"/>
              </event>
              <event>
                <sub_title>Device Embolization Left Ventricle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1814"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edwards THV Clinical Affairs</name_or_title>
      <organization>Edwards Lifesciences</organization>
      <phone>949-250-2500</phone>
      <email>THV_CT.gov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

